The ISPOR Europe 2022 Global Conference for Health Economics and Outcomes Research (HEOR) was held this year on 6-9 November, in-person in Vienna and virtually for discussion and dissemination of the latest trends in healthcare.
This year’s conference theme was: Collaborating Across Borders: Building & Using Evidence to Enable Access.
The conference provided attendees with opportunities to network in-person and virtually with your peers, HEOR experts, and thought leaders and to discuss with a global audience how we establish, incentivize, and share value sustainable for health systems, patients, and technology developers.
We were thrilled that our co-authored Abstract Poster, titled: “Cost Utility and Budget Impact of Closed Loop Upper Airway Stimulation (UAS) for the Treatment of Moderate to Severe Obstructive Sleep Apnea from an Australian Health Care System Perspective”, was selected and presented as Poster EE69 at The ISPOR Europe 2022 Global Conference, in Vienna on Monday, 07 November by our partners Hemant Rathi and Amit Gupta. from Skyward Analytics.
Poster title: “Cost Utility and Budget Impact of Closed Loop Upper Airway Stimulation (UAS) for the Treatment of Moderate to Severe Obstructive Sleep Apnea from an Australian Health Care System Perspective”, co-authored by our Partner and Director, George Papadopoulos, Sarah Griffin, Hemant Rathi and Amit Gupta.
VIEW AND DOWNLOAD THE FULL POSTER HERE
About the Author
George Papadopoulos, BSc(Hons), GDipEpi, MAICD
George is a healthcare pricing and reimbursement professional with over 25 years’ experience across in local and international healthcare companies. George worked in both local operating company and global levels in increasing levels of responsibility for leading pharmaceutical companies in Australia, Belgium and the United States. He has previously worked for Pharmacia, Johnson and Johnson, Schering-Plough and Merck. George has experience in the pharmaceutical, biotech and medical device industry, including clinical research, health economics, reimbursement and pricing.
George is currently Partner and Director of Lucid Health Consulting, a strategic healthcare consultancy providing services to assist healthcare companies with the market access for their pharmaceutical, biotech, medical device or diagnostic technologies. These services include health economics strategy, health technology assessment, pricing and reimbursement strategy development and advisory board participation.
George received his BSc(Hons) from the University of Sydney and Grad Dip Epi(Pharmacoepi) from University of Newcastle. He is Past-President of the Board of ARCS; Member of Heath Economics Expert Panel of Ausbiotech and a member of HTAi (Health Technology Association International), iHEA (International Health Economics Association), ISPOR and ISPOR Australian Chapter and of the AICD (Australian Institute of Company Directors).